Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Invitae | History Defined

Invitae's Court-Approved Bankruptcy Sale Set for Five Months

Invitae, a leading medical genetics company, has received court approval for a five-month bankruptcy sale. The sale process will allow Invitae to repay its...

Vital medical tests evade regulation

Vital medical tests evade regulation

Money and lobbying help shield lab-developed tests, including prenatal screenings, from heightened federal scrutiny

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022

Analyst Ratings for Invitae

Within the last quarter, Invitae (NYSE:NVTA) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

Invitae Earnings Perspective: Return On Capital Employed

Invitae Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q1, Invitae (NYSE:NVTA) posted sales of $123.69 million. Earnings were up 11.34%, but Invitae still reported an overall loss of $181.86 million.

Analyst Ratings for Invitae

Analyst Ratings for Invitae

Analysts have provided the following ratings for Invitae (NYSE:NVTA) within the last quarter:

Is Invitae Stock a Buy Under $5?

Is Invitae Stock a Buy Under $5?

Invitae's (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around the stock. However, given the company's widening losses and poor profitability, the question is, is it worth betting on the stock at the…

Recap: Invitae Q1 Earnings

Recap: Invitae Q1 Earnings

Invitae (NYSE:NVTA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Invitae missed estimated earnings by 2.63%, reporting an EPS of $-0.78 versus an estimate of $-0.76.

Expert Ratings for Invitae

Expert Ratings for Invitae

Over the past 3 months, 4 analysts have published their opinion on Invitae (NYSE:NVTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation

Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation

Invitae Corp's (NASDAQ: NVTA)

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Paramount Global

Micron Technology

Palantir Technologies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play